Chronic Spontaneous Urticaria
Chronic spontaneous urticaria (CSU) is a common inflammatory skin condition characterized by recurrent wheals (hives), itching and sometimes angioedema for more than six weeks. It can significantly affect sleep, daily activities and overall quality of life. CSU is primarily driven by activation of mast cells and basophils and may involve different immune mechanisms.
What Is Chronic Spontaneous Urticaria?
Urticaria is generally classified into acute urticaria, which lasts less than six weeks, and chronic urticaria, which continues for more than six weeks.
Chronic urticaria includes:
- Chronic spontaneous urticaria (CSU): Symptoms occur without a consistent external physical trigger.
- Chronic inducible urticaria (CIndU): Symptoms are triggered by specific physical or environmental stimuli.
Some patients can have both CSU and CIndU.
Symptoms and Triggers
The most common symptoms of CSU are:
- Itchy, raised wheals or hives
- Redness and skin irritation
- Swelling of deeper tissues (angioedema)
- Recurrent episodes that may appear and disappear over time
In CIndU, symptoms may be triggered by factors such as scratching, cold, pressure, changes in temperature, sunlight, water, exercise or direct contact.
CSU may also occur alongside allergic conditions such as allergic rhinitis, allergic conjunctivitis, asthma and atopic dermatitis.
Why Does CSU Occur?
CSU is primarily associated with activation and degranulation of mast cells and basophils. Two major immune mechanisms have been proposed:
Type I Auto-Allergy
In this mechanism, specific IgE antibodies may recognize the body’s own proteins, or auto-allergens, and contribute to mast-cell activation.
Type IIb Autoimmunity
Some patients have IgG autoantibodies directed against IgE or the high-affinity IgE receptor (FcεRI). These antibodies may activate mast cells and basophils and contribute to persistent symptoms.
Histamine is an important mediator of itching, although other inflammatory mediators and nerve-related pathways may also contribute.
Assessing Disease Activity and Control
Monitoring disease activity helps doctors understand how well treatment is working.
Urticaria Activity Score (UAS7)
UAS7 records the severity of wheals and itching over seven consecutive days. Higher scores indicate greater disease activity.
Urticaria Control Test (UCT)
The UCT is a short questionnaire used to assess how well urticaria is controlled. Lower scores indicate poorer disease control.
Other tools, including the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) and Angioedema Quality of Life Questionnaire (AE-QoL), can help assess the impact of the condition on everyday life.
Diagnosis and Biomarkers
Diagnosis is mainly based on the patient’s history, clinical examination and appropriate investigations to exclude other causes and identify associated conditions.
Certain clinical and laboratory findings have been associated with disease activity or treatment response, including:
- Total IgE levels
- D-dimer
- C-reactive protein (CRP)
- Basophil and eosinophil counts
- Thyroid autoimmunity
- Other inflammatory markers
These markers may provide additional information, but treatment decisions should be based on the complete clinical picture.
Stepwise Treatment of CSU
Current treatment approaches use a stepwise strategy, with the goal of achieving good disease control.
Second-Generation Antihistamines
Second-generation H1 antihistamines are generally used as the initial treatment. In patients who do not respond adequately, the dose may be increased up to four times the standard dose under medical supervision.
Omalizumab
For patients whose CSU remains uncontrolled despite appropriate antihistamine treatment, omalizumab, an anti-IgE monoclonal antibody, is an important treatment option.
Omalizumab binds free IgE, reducing IgE availability and subsequently decreasing FcεRI receptor expression on mast cells and basophils. This can reduce the activation of these cells and improve urticaria symptoms.
The source discusses 300 mg every four weeks as the commonly used dose in CSU, with other dosing strategies considered in selected patients under specialist supervision.
How Long Is Omalizumab Used?
The duration of omalizumab treatment varies between patients. Some experience a rapid response, while others may require several injections before achieving adequate control.
Symptoms can return after treatment is stopped, and some patients may require additional treatment cycles. There is currently no universally accepted method for gradually withdrawing or spacing treatment.
Omalizumab in Special Situations
Omalizumab has also been studied in patients with CSU accompanied by angioedema and in certain cases of chronic inducible urticaria.
Children and Adolescents
The source describes established use in patients aged 12 years and above, while evidence in younger children remains limited. Treatment in children should therefore be guided by an experienced specialist and applicable regulatory recommendations.
Pregnancy
Evidence regarding omalizumab during pregnancy is limited. Decisions regarding its use during pregnancy should be individualized and made by the treating specialist after considering potential benefits and risks.
Older and Obese Patients
Evidence in people over 65 years and in patients with obesity is more limited. Some studies described in the source have reported differences in treatment response in obese patients.
When Omalizumab Does Not Work
Not every patient responds to omalizumab. The source identifies factors such as low baseline total IgE, certain autoimmune patterns, increased inflammatory markers and obesity as possible characteristics associated with poorer or slower response.
Ligelizumab
Ligelizumab is another anti-IgE monoclonal antibody that has been investigated for CSU. It acts by strongly inhibiting the interaction between IgE and the high-affinity FcεRI receptor.
Research described in the source suggests that ligelizumab may provide prolonged suppression of free IgE compared with omalizumab. However, further clinical studies are needed to establish its role and long-term use in CSU.
Living With Chronic Urticaria
CSU can be persistent and unpredictable, but appropriate assessment and treatment can substantially improve symptom control and quality of life.
Regular monitoring of symptoms using tools such as UAS7 and UCT can help healthcare professionals evaluate treatment response and make appropriate adjustments.
Conclusion
Chronic spontaneous urticaria is a complex mast-cell-driven condition involving multiple immune mechanisms. Diagnosis is primarily clinical, supported by appropriate investigations and assessment of disease activity.
Treatment generally follows a stepwise approach, beginning with second-generation antihistamines and progressing to therapies such as omalizumab when symptoms remain uncontrolled. Other anti-IgE treatments, including ligelizumab, continue to be investigated.
Because CSU can vary considerably between individuals, treatment should be individualized according to symptoms, disease control, associated conditions and response to therapy.










